As shown in Figure 4A, 6 out of 13 (46%) HCC patients displayed a MAGE-A-specific CD8+ T-cell response prior therapy and 6 out of 13 (46%) patients after TACE and therefore no increase in the circulating TAA-specific T-cell response was observed. Here, CD8A is linked to hepatocellular carcinoma.